Sanofi's billion-euro investment plans in Frankfurt, Germany are now official: the French pharmaceutical company is investing around €1.3 billion in the construction of a...
Plans by major insulin producers Eli Lilly, NovoNordisk and Sanofi to drop their prices may be undercutting the US state of California’s state-backed generic insulin...
The world's largest insulin producers, Eli Lilly, NovoNordisk and Sanofi are now marching (almost) in lockstep to reduce US market prices, but not without tossing...
Danish drugmaker Novo Nordisk has added its name to the list of insulin producers cutting prices for US retail buyers, following up on Eli Lilly’s announcement of price...
As the discussion surrounding the high price of insulin in the US continues unabated, drugmaker Eli Lilly implemented price reductions of 70% for its most commonly...
18.12.2018
- Scott Gottlieb, Commissioner of the US Food and Drug Administration is focusing on insulin drugs in the current round of the government’s efforts to lower pharmaceutical prices...
24.01.2018
- Sandoz, the generics subsidiary of Novartis, is collaborating with Biocon, an India-based biopharmaceuticals producer, to develop, manufacture and commercialize multiple...
07.11.2017
- Sanofi is pursuing another US competitor for alleged breach of the patent for its top-selling diabetes drug insulin glargine (branded as Lantus and Lantus SoloStar), which together...
